107 related articles for article (PubMed ID: 9024672)
1. Characterization of the high sensitivity of rabbits to the effects of TCV-116, an angiotensin II receptor antagonist.
Sato K; Chatani F; Ito K; Kito G
Fundam Appl Toxicol; 1997 Jan; 35(1):49-54. PubMed ID: 9024672
[TBL] [Abstract][Full Text] [Related]
2. Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension.
Ito K; Shiomi M; Kito G
Hypertens Res; 1995 Mar; 18(1):69-75. PubMed ID: 7584913
[TBL] [Abstract][Full Text] [Related]
3. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
Kanagawa R; Wada T; Sanada T; Ojima M; Inada Y
Jpn J Pharmacol; 1997 Mar; 73(3):185-90. PubMed ID: 9127812
[TBL] [Abstract][Full Text] [Related]
4. Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats.
Wada T; Kanagawa R; Ishimura Y; Inada Y; Nishikawa K
J Hypertens; 1995 Jan; 13(1):113-22. PubMed ID: 7759841
[TBL] [Abstract][Full Text] [Related]
5. Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats.
Naeshiro I; Sato K; Chatani F; Sato S
Eur J Pharmacol; 1998 Aug; 354(2-3):179-87. PubMed ID: 9754919
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.
Nishikawa K; Inada Y; Shibouta Y; Wada T; Ojima M; Kubo K; Naka T
Blood Press Suppl; 1994; 5():7-14. PubMed ID: 7889205
[TBL] [Abstract][Full Text] [Related]
7. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension.
Kawabata M; Takabatake T; Ohta H; Nakamura S; Hara H; Ohta K; Takakuwa H; Han WH; Kobayashi K
Blood Press Suppl; 1994; 5():117-21. PubMed ID: 7889193
[TBL] [Abstract][Full Text] [Related]
8. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man.
Schmitt F; Natov S; Martinez F; Lacour B; Hannedouche TP
Clin Sci (Lond); 1996 Mar; 90(3):205-13. PubMed ID: 8777826
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers.
Delacrétaz E; Nussberger J; Biollaz J; Waeber B; Brunner HR
Hypertension; 1995 Jan; 25(1):14-21. PubMed ID: 7843746
[TBL] [Abstract][Full Text] [Related]
10. Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects.
Ogihara T; Nagano M; Mikami H; Higaki J; Kohara K; Azuma J; Aoki T; Hamanaka Y
Clin Ther; 1994; 16(1):74-86. PubMed ID: 8205603
[TBL] [Abstract][Full Text] [Related]
11. Nonpeptide angiotensin II type 1 receptor antagonist prevents nephrosclerosis in hypertensive rats.
Kanno Y; Okada H; Suzuki H; Ikenaga H; Saruta T
Blood Press Suppl; 1994; 5():67-70. PubMed ID: 7889204
[TBL] [Abstract][Full Text] [Related]
12. A case of renin-producing juxtaglomerular tumor: effect of ACE inhibitor or angiotensin II receptor antagonist.
Kashiwabara H; Inaba M; Itabashi A; Ishii J; Katayama S
Blood Press; 1997 May; 6(3):147-53. PubMed ID: 9181252
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of a new angiotensin II receptor antagonist, TCV-116: effects of a single oral dose on blood pressure in patients with essential hypertension.
Ogihara T; Higashimori K; Masuo K; Mikami H
Clin Ther; 1993; 15(4):684-91. PubMed ID: 8221818
[TBL] [Abstract][Full Text] [Related]
14. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions.
Kito G; Ito K; Shiomi M
Arzneimittelforschung; 1996 Jul; 46(7):681-6. PubMed ID: 8842337
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury.
Yoshiyama M; Kim S; Yamagishi H; Omura T; Tani T; Yanagi S; Toda I; Teragaki M; Akioka K; Takeuchi K
Am Heart J; 1994 Jul; 128(1):1-6. PubMed ID: 8017262
[TBL] [Abstract][Full Text] [Related]
16. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
[TBL] [Abstract][Full Text] [Related]
17. Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects.
Schmitt F; Martinez F; Brillet G; Nguyen-Khoa T; Brouard R; Sissmann J; Lacour B; Grunfeld JP
J Cardiovasc Pharmacol; 1998 Feb; 31(2):314-21. PubMed ID: 9475275
[TBL] [Abstract][Full Text] [Related]
18. Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
Okada H; Suzuki H; Kanno Y; Ikenaga H; Saruta T
J Cardiovasc Pharmacol; 1995 Oct; 26(4):564-9. PubMed ID: 8569216
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of hypertension and renal injury by salt-loading during chronic nitric oxide inhibition. Effects of TCV-116, a novel angiotensin II receptor antagonist.
Okamura M; Konishi Y; Nishimura M; Umetani N; Iwai J; Negoro N; Inoue T; Takeda T; Kanayama Y
Blood Press Suppl; 1994; 5():75-8. PubMed ID: 7889207
[TBL] [Abstract][Full Text] [Related]
20. Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury.
Kim S; Ohta K; Hamaguchi A; Omura T; Yukimura T; Miura K; Inada Y; Wada T; Ishimura Y; Chatani F
Kidney Int; 1994 Nov; 46(5):1346-58. PubMed ID: 7853793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
